(19)
(11) EP 1 189 895 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.11.2005 Bulletin 2005/45

(45) Mention of the grant of the patent:
08.06.2005 Bulletin 2005/23

(21) Application number: 00943847.4

(22) Date of filing: 22.06.2000
(51) International Patent Classification (IPC)7C07D 277/24, C07D 277/26, C07D 263/32, A61K 31/421, A61K 31/426, A61P 3/10
(86) International application number:
PCT/EP2000/005720
(87) International publication number:
WO 2001/000603 (04.01.2001 Gazette 2001/01)

(54)

THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE

THIAZOL- UND OXAZOL-DERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNG

DERIVES DE THIAZOL ET D'OXAZOLE ET UTILISATION PHARMACEUTIQUE DE CEUX-CI


(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
SI

(30) Priority: 25.06.1999 GB 9914977

(43) Date of publication of application:
27.03.2002 Bulletin 2002/13

(73) Proprietor: SMITHKLINE BEECHAM CORPORATION
Philadelphia, Pennsylvania 19101 (US)

(72) Inventors:
  • CHAO, Esther, Yu-Hsuan
    Research Triangle Park, NC 27709 (US)
  • HAFFNER, Curt, Dale
    Research Triangle Park, NC 27709 (US)
  • LAMBERT, Millard, Hurst, III
    Research Triangle Park, NC 27709 (US)
  • MALONEY, Patrick, Reed
    Research Triangle Park, NC 27709 (US)
  • SIERRA, Michael, Lawrence
    91940 Les Ulis (FR)
  • STERNBACH, Daniel, David
    Research Triangle Park, NC 27709 (US)
  • SZNAIDMAN, Marcos, Luis
    Durham, NC 27713 (US)
  • WILLSON, Timothy, Mark
    Research Triangle Park, NC 27709 (US)
  • XU, Huaqiang, Eric
    Research Triangle Park, NC 27709 (US)
  • GELLIBERT, Françoise, Jeanne, Lab. Glaxo Wellcome
    91940 Les Ulis (FR)

(74) Representative: Learoyd, Stephanie Anne et al
GlaxoSmithKline Two New Horizons Court Horizons Court
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A-97/28149
WO-A-99/04815
US-A- 5 847 008
WO-A-98/07699
WO-A-99/46232
   
  • PATENT ABSTRACTS OF JAPAN vol. 1997, no. 04, 30 April 1997 (1997-04-30) & JP 08 325250 A (SUMITOMO METAL IND LTD), 10 December 1996 (1996-12-10) -& JP 08 325250 A 10 December 1996 (1996-12-10)
  • H. SHINKAI ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 11, 1998, pages 1927-33, XP002151949
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).